[16] Payal Deepak Shah, et al.HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.2024 ASCO abstract 10616. [17]Morganti S, Marra A, De Angelis ...
乳腺癌易感基因(breast cancer susceptibility gene, BRCA)与乳腺癌有着密不可分的关系。 BRCA基因 的两个成员,即BRCA1和2,分别是在1990年和1994年被分离。 乳腺癌可以分为 遗传性乳腺癌 和 散发性乳腺癌 (sporadic breast cancer),散发性乳腺癌指的是没有发现明确的遗传基因改变(完整的癌变点)与乳腺癌家族史...
https://www.targetedonc.com/view/fda-approves-olaparib-as-adjuvant-treatment-for-brca-mutated-her2-negative-breast-cancer haoeyou.com/zhongliu_aizheng/ruxianai/20220316/7089.html 「文中图片来源Pixabay,均已获版权方授权」
[Abstract]Germline mutations inBRCAgenes (includingBRCA1/2) are the major risk factors for hereditary tumors including breast and ovarian cancer. Population basedBRCAgene screening, particularly in high-risk individuals with a ...
(Tutt A N J, Garber J E, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer[J]. New England Journal of Medicine, 2021, 384(25): 2394-2405.) 这项研究一共入组了1836名BRCA突变的乳腺癌患者,这些患者中,80%左右是三阴性乳腺癌,20%左右是HER2-HR+...
[1]. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112 [2]. Walsh T, Gulsuner S, Lee MK, et al. Inherited predisposition to breas...
7. Rivenbark A, et al. Molecular and Cellular Heterogeneity in Breast Cancer: Challenges for Personalized Medicine. Am J Pathol. 2013;183(4):1113-1124.8. Roy R, et al. BRCA1 and BRCA2: Different Roles in a Common Pathway of Genome Protection. Nat Rev Cancer. 2021;12(1):68–78.9....
BRCA基因，即乳腺癌易感基因（Breast cancer susceptibility gene），包括BRCA1和BRCA2两种类型，它们在20世纪90年代被科学家们发现。这些基因位于我们的第17号和第13号染色体上，扮演着抑癌基因的角色，主要参与DNA损伤修复和转录调控。它们可以被比喻为我们体内的“哨兵”，时刻守护着细胞的健康，防止它们走向癌变的...
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with
参考文献:Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol.